Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in…
neuroendocrine tumors
Results of the DUTHY exploratory phase II study evaluating dual immune checkpoint blockade with durvalumab and tremelimumab show promising activity…
